Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 3

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 3
---

| • |     | Takeda applies International Financial Reporting Standards (IFRS), and the disclosure information in this document is based on IFRS. |

| • |     | All forecasts and management guidance in this document are based on information and assumptions currently available to management, and do not represent a promise or guarantee to achieve these forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuations in foreign exchange rates. Should any significant event occur which requires the forecasts or guidance to be revised, Takeda will disclose it in a timely manner. |

| • |     | For details of the forecasts for consolidated operating results and the management guidance, please refer to "1. Financial Highlights for the Six-month Period Ended September 30, 2025 (4) Outlook for the Fiscal Year Ending March 31, 2026" on page12. |

(Takeda Website):

https://www.takeda.com/investors/financial-results/quarterly-results/

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

#### Attachment Index
| 1. Financial Highlights for the Six-month Period Ended September 30, 2025     |     |  2 |
|:------------------------------------------------------------------------------|:----|---:|
| (1) Business Performance                                                      |     |  2 |
| (2) Consolidated Financial Position                                           |     |  9 |
| (3) Consolidated Cash Flow                                                    |     | 11 |
| (4) Outlook for the Fiscal Year Ending March 31, 2026                         |     | 12 |
| (5) Interim Dividend for Fiscal 2025                                          |     | 14 |
| 2. Condensed Interim Consolidated Financial Statements [IFRS] and Major Notes |     | 15 |
| (1) Condensed Interim Consolidated Statements of Profit or Loss               |     | 15 |
| (2) Condensed Interim Consolidated Statements of Comprehensive Income         |     | 16 |
| (3) Condensed Interim Consolidated Statements of Financial Position           |     | 17 |
| (4) Condensed Interim Consolidated Statements of Changes in Equity            |     | 19 |
| (5) Condensed Interim Consolidated Statement of Cash Flows                    |     | 21 |
| (